AOA Dx Demonstrates High Accuracy in AI-Powered Blood Test for Ovarian Cancer Detection in 1,000 Symptomatic Patient Samples

AOA Dx presented new data at the 2025 AACR Annual Meeting demonstrating high accuracy in early detection of ovarian cancer using its AI-powered multi-omic platform. In collaboration with CU Anschutz Ovarian Cancer Innovations Group (OCIG) and The University of Manchester, the platform achieved AUCs over 90% across approximately 1,000 real-world symptomatic patient samples, outperforming traditional biomarkers like CA125. These results highlight the potential of AOA Dx’s liquid biopsy to aid earlier, more accurate diagnosis and improve outcomes for women worldwide.

AOA Dx Joins BLOODPAC to Accelerate Early Detection of Ovarian Cancer with Liquid Biopsy Innovations

AOA Dx is excited to join the BLOODPAC Consortium, a public-private initiative dedicated to advancing liquid biopsy technologies for cancer detection. Through this partnership, AOA Dx will contribute its expertise in lipidomics and multi-omics to help establish standards for early detection assays, particularly in ovarian cancer. With a commitment to scientific collaboration, AOA Dx plans to share its research on gangliosides, lipids, and proteins, furthering the integration of liquid biopsy into clinical practice.

AOA Dx to Present Latest Research on Tumor-Marker Gangliosides for Early Detection of Ovarian Cancer at International Liquid Biopsy Conference

AOA Dx will showcase its latest research at the International Society of Liquid Biopsy conference (November 23–25, 2024), presenting findings from the study “Identification of Tumor-Marker Gangliosides in Serum for Early-Stage Cancer Diagnosis.” This research underscores the promise of tumor-marker gangliosides (TMGs) as biomarkers for early ovarian cancer detection.

AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer with early detection and high accuracy, and to expand their GlycoLocate™ Platform to target a broader range of cancers

AOA Dx is announcing an oversubscribed $17 million round led by Good Growth Capital with participation from leading investors including RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund. Several funds invested for the second time, underpinning the continuous success of AOA Dx across the last year.

AOA Dx Announces First Patient Enrolled in OVERT Clinical Study Evaluating the AKRIVIS GD™ test for Early Detection of Ovarian Cancer

AOA Dx today announced that the first patient has been enrolled in their OVERT (Ovarian Cancer Early Detection Research) clinical trial. The OVERT trial is a multi-center national trial, the first of its kind in a symptomatic U.S. population. AOA Dx is working with world renowned clinicians and healthcare institutions across the US to bring to market the first test for the early detection of ovarian cancer.